Cargando…

Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer

INTRODUCTION: Mitochondria are a significant target of lonidamine (LND). However, its limited solubility and inability to specifically target mitochondria, LND can lead to hepatic toxicity and has shown only modest anticancer activity. The objective of this study is to establish a glutathione progra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhongjie, Qin, Yanru, Wang, Xueyuan, Zhang, Tianyu, Hu, Yixue, Wang, Dongna, Zhang, Liefeng, Zhu, Yongqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378575/
https://www.ncbi.nlm.nih.gov/pubmed/37520302
http://dx.doi.org/10.2147/IJN.S413217
_version_ 1785079801405505536
author Wang, Zhongjie
Qin, Yanru
Wang, Xueyuan
Zhang, Tianyu
Hu, Yixue
Wang, Dongna
Zhang, Liefeng
Zhu, Yongqiang
author_facet Wang, Zhongjie
Qin, Yanru
Wang, Xueyuan
Zhang, Tianyu
Hu, Yixue
Wang, Dongna
Zhang, Liefeng
Zhu, Yongqiang
author_sort Wang, Zhongjie
collection PubMed
description INTRODUCTION: Mitochondria are a significant target of lonidamine (LND). However, its limited solubility and inability to specifically target mitochondria, LND can lead to hepatic toxicity and has shown only modest anticancer activity. The objective of this study is to establish a glutathione programmed mitochondria targeted delivery of LND for the effective treatment of triple negative breast cancer (TNBC). METHODS: In this study, LND was encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) wrapped with mitochondria-targeting short-chain triphenylphosphonium-tocopherol polyethylene glycol succinate (TPP-TPGS, TPS) and tumor-targeting long-chain 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-S-S-polyethylene glycol-R6RGD (DSPE-S-S-PEG(2000)-R6RGD, DSSR), which were designated as LND-PLGA/TPS/DSSR NPs. The release behavior was evaluated, and cellular uptake, in vitro and in vivo antitumor activity of nanoparticles were investigated. The mechanism, including apoptosis of tumor cells and mitochondrial damage and respiratory rate detection, was also further investigated. RESULTS: LND-PLGA/TPS/DSSR NPs were successfully prepared, and characterization revealed that they are globular particles with smooth surfaces and an average diameter of about 250 nm. Long-chain DSSR in LND-PLGA/TPS/DSSR NPs prevented positively charged LND-PLGA/TPS NPs from being cleared by the reticuloendothelial system. Furthermore, LND release rate from NPs at pH 8.0 was significantly higher than that at pH 7.4 and 5.5, which demonstrated specific LND release in mitochondria and prevented LND leakage in cytoplasm and lysosome. NPs could locate in mitochondria, and the released LND triggered apoptosis of tumor cells by damaging mitochondria and releasing apoptosis-related proteins. In addition, in TNBC mice model, programmed mitochondria targeted NPs improved efficacy and reduced LND toxicity. CONCLUSION: LND-PLGA/TPS/DSSR NPs may be a useful system and provide an effective approach for the treatment of TNBC.
format Online
Article
Text
id pubmed-10378575
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-103785752023-07-29 Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer Wang, Zhongjie Qin, Yanru Wang, Xueyuan Zhang, Tianyu Hu, Yixue Wang, Dongna Zhang, Liefeng Zhu, Yongqiang Int J Nanomedicine Original Research INTRODUCTION: Mitochondria are a significant target of lonidamine (LND). However, its limited solubility and inability to specifically target mitochondria, LND can lead to hepatic toxicity and has shown only modest anticancer activity. The objective of this study is to establish a glutathione programmed mitochondria targeted delivery of LND for the effective treatment of triple negative breast cancer (TNBC). METHODS: In this study, LND was encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) wrapped with mitochondria-targeting short-chain triphenylphosphonium-tocopherol polyethylene glycol succinate (TPP-TPGS, TPS) and tumor-targeting long-chain 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-S-S-polyethylene glycol-R6RGD (DSPE-S-S-PEG(2000)-R6RGD, DSSR), which were designated as LND-PLGA/TPS/DSSR NPs. The release behavior was evaluated, and cellular uptake, in vitro and in vivo antitumor activity of nanoparticles were investigated. The mechanism, including apoptosis of tumor cells and mitochondrial damage and respiratory rate detection, was also further investigated. RESULTS: LND-PLGA/TPS/DSSR NPs were successfully prepared, and characterization revealed that they are globular particles with smooth surfaces and an average diameter of about 250 nm. Long-chain DSSR in LND-PLGA/TPS/DSSR NPs prevented positively charged LND-PLGA/TPS NPs from being cleared by the reticuloendothelial system. Furthermore, LND release rate from NPs at pH 8.0 was significantly higher than that at pH 7.4 and 5.5, which demonstrated specific LND release in mitochondria and prevented LND leakage in cytoplasm and lysosome. NPs could locate in mitochondria, and the released LND triggered apoptosis of tumor cells by damaging mitochondria and releasing apoptosis-related proteins. In addition, in TNBC mice model, programmed mitochondria targeted NPs improved efficacy and reduced LND toxicity. CONCLUSION: LND-PLGA/TPS/DSSR NPs may be a useful system and provide an effective approach for the treatment of TNBC. Dove 2023-07-24 /pmc/articles/PMC10378575/ /pubmed/37520302 http://dx.doi.org/10.2147/IJN.S413217 Text en © 2023 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Zhongjie
Qin, Yanru
Wang, Xueyuan
Zhang, Tianyu
Hu, Yixue
Wang, Dongna
Zhang, Liefeng
Zhu, Yongqiang
Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
title Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
title_full Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
title_fullStr Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
title_full_unstemmed Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
title_short Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
title_sort glutathione programmed mitochondria targeted delivery of lonidamine for effective against triple negative breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378575/
https://www.ncbi.nlm.nih.gov/pubmed/37520302
http://dx.doi.org/10.2147/IJN.S413217
work_keys_str_mv AT wangzhongjie glutathioneprogrammedmitochondriatargeteddeliveryoflonidamineforeffectiveagainsttriplenegativebreastcancer
AT qinyanru glutathioneprogrammedmitochondriatargeteddeliveryoflonidamineforeffectiveagainsttriplenegativebreastcancer
AT wangxueyuan glutathioneprogrammedmitochondriatargeteddeliveryoflonidamineforeffectiveagainsttriplenegativebreastcancer
AT zhangtianyu glutathioneprogrammedmitochondriatargeteddeliveryoflonidamineforeffectiveagainsttriplenegativebreastcancer
AT huyixue glutathioneprogrammedmitochondriatargeteddeliveryoflonidamineforeffectiveagainsttriplenegativebreastcancer
AT wangdongna glutathioneprogrammedmitochondriatargeteddeliveryoflonidamineforeffectiveagainsttriplenegativebreastcancer
AT zhangliefeng glutathioneprogrammedmitochondriatargeteddeliveryoflonidamineforeffectiveagainsttriplenegativebreastcancer
AT zhuyongqiang glutathioneprogrammedmitochondriatargeteddeliveryoflonidamineforeffectiveagainsttriplenegativebreastcancer